Key facts
- This page summarizes Jeffrey Trigilio's Form 4 filing for Cullinan Oncology, Inc. (CGEM).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 23 Feb 2024, 17:00.
Jeffrey Trigilio - 22 Feb 2024 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CGEM
- Reported as of
- 22 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Feb 2024, 17:00:15 UTC
- Prior SEC filing
- 22 Dec 2023
- Next SEC filing
- 14 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jacquelyn Sumer, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey Trigilio filed Form 4 for Cullinan Oncology, Inc. (CGEM) on 23 Feb 2024.
Change
- Previous filing in this sequence was filed on 22 Dec 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CGEM
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- +60%
- Price
- $0.000000
- Shares after
- 133,919
- Date
- 22 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CGEM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- Price
- $0.000000
- Shares after
- 100,000
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $17.54
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares underlying the restricted stock unit vest on an annual basis over four years.
Footnote F2
The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.